RCM
HAE icon

Raleigh Capital Management’s Haemonetics HAE Stock Holding History

Raleigh Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-82
Closed -$7.01K – 1054
2023
Q4 		$7.01K Buy
82
+8
+11% +$692 ﹤0.01% 674
2023
Q3 		$6.63K Buy
74
+8
+12% +$714 ﹤0.01% 630
2023
Q2 		$5.62K Buy
+66
New +$5.58K ﹤0.01% 621

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raleigh Capital Management's HAE Position: Q1 2024 in Review

Raleigh Capital Management sold out of Haemonetics (HAE) in Q1 2024, closing a stake of 82 shares — an estimated $7.01K sold.

Raleigh Capital Management first reported a position in HAE in Q2 2023 and held it in 3 quarters. The position peaked at $7.01K in Q4 2023. 298 funds tracked by Wall St. Rank hold HAE as of Q1 2024.

  • Raleigh Capital Management reported no remaining Haemonetics position as of Q1 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 82 Haemonetics shares in Q1 2024, an estimated $7.01K.
  • Raleigh Capital Management first reported a position in Haemonetics in Q2 2023 and held it in 3 quarters.
  • Raleigh Capital Management's Haemonetics position peaked at $7.01K in Q4 2023.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q1 2024.

Based on Raleigh Capital Management's 13F filing for Q1 2024, filed 13 May 2024.